{\rtf1\deflang1033\deflangfe1033\margl720\margr720\margt360\margb360{\stylesheet{\fs20\lang1033\snext0 Normal;} {\s1\sb240\keepn{\*\pn \pnlvl1\pndec\pnprev1\pnstart1\pnsp144}\b\f0\fs30\lang1033 \sbasedon0\snext0 heading 1;} {\s2\sb200\keepn{\*\pn \pnlvl2\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs26\lang1033 \sbasedon0\snext0 heading 2;} {\s3\sb180\keepn{\*\pn \pnlvl3\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 3;} {\s4\sb160\keepn{\*\pn \pnlvl4\pnucltr\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 4;} {\s5\sb140\keepn{\*\pn \pnlvl5\pncltr\pnprev1\pnstart1\pnsp144}\b\f0\fs20\lang1033 \sbasedon0\snext0 heading 5;} {\s6\tqc\lang1033\sbasedon0\snext6 footer;} {\*\cs16 \additive\super\sbasedon10 footnote reference;} {\*\cs18 \additive\sbasedon10 page number;}} {\fonttbl{\f0\fnil Times New Roman;}{\f1\fnil Courier New}{\f2005\fnil Courier New;}{\f2010\fnil Wingdings;}{\f2020\fnil Webdings;}{\f2\fnil Arial;}{\f3\fnil Arial;}{\f4\fnil LucidaHandwriting;}{\f5\fnil Symbol;}{\f6\fnil Symbol;}{\f7\fnil Ferdsch;}{\f30\fnil Myriad Cn Semibold;}{\f31\fnil Myriad Roman;}{\f50\fnil Courier New;}{\f51\fnil Times New Roman;}{\f52\fnil Arial;}{\f53\fnil Symbol;}{\f54\fnil Wingdings;}{\f55\fnil Wingdings 2;}{\f56\fnil Wingdings 3;}{\f57\fnil Webdings;}{\f58\fnil Arial Narrow;}{\f59\fnil Arial Unicode MS;}{\f60\fnil Cyberbit;}{\f61\fnil Morningstar 1U Light;}{\f62\fnil Calibri;}} {\colortbl;\red0\green0\blue0;\red127\green0\blue0;\red0\green0\blue255;\red127\green127\blue127;\red0\green51\blue153;\red255\green204\blue0;\red255\green255\blue255;\red246\green244\blue236;\red0\green0\blue0;} {\*\bkmkstart filing_1}{\*\bkmkend filing_1}{\*\bkmkstart doc_1_1}{\*\bkmkend doc_1_1}\par\pard\plain\brdrb\brdrs\cf1\f51\fs2\ql \~\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc UNITED STATES\par\pard\plain\cf1\f51\fs20\b\qc SECURITIES AND EXCHANGE COMMISSION\par\pard\plain\cf1\f51\fs20\qc Washington, D.C. 20549\par\pard\plain\cf1\f51\fs20\ql \~\~\~\par\pard\plain\sa308\cf1\f51\fs20\qc FORM 8-K\par\pard\plain\cf1\f51\fs20\b\qc CURRENT REPORT\par\pard\plain\cf1\f51\fs20\b\qc PURSUANT TO SECTION 13 OR 15(d) OF THE\par\pard\plain\cf1\f51\fs20\qc SECURITIES EXCHANGE ACT OF 1934\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc Date of Report (Date of earliest event reported): March 27, 2018\~\par\pard\plain\sb22\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql \~\~ \par\pard\plain {\trowd\clbrdrb\brdrs\brdrcf1\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\b\qc TherapeuticsMD, Inc.\cell{ {\trowd\clbrdrb\brdrs\brdrcf1\cellx10800\trrh248\row}}} {\trowd\cellx10800\trrh248 \pard\plain\intbl\li110\ri110\cf1\f51\fs20\qc (Exact Name of Registrant as Specified in its Charter)\cell{ {\trowd\cellx10800\trrh248\row}}}\pard\plain\fi594\cf1\f51\fs20\qc \~ \par\pard\plain {\trowd\clbrdrb\brdrs\brdrcf1\cellx3456\cellx3672\clbrdrb\brdrs\brdrcf1\cellx7128\cellx7343\clbrdrb\brdrs\brdrcf1\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\b\qc Nevada\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\qc 001-00100\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\qc 87-0233535\cell{ {\trowd\clbrdrb\brdrs\brdrcf1\cellx3456\cellx3672\clbrdrb\brdrs\brdrcf1\cellx7128\cellx7343\clbrdrb\brdrs\brdrcf1\cellx10800\trrh248\row}}} {\trowd\cellx3456\cellx3672\cellx7128\cellx7343\cellx10800\trrh495 \pard\plain\intbl\cf1\f51\fs20\qc (State or Other\par\pard\plain\intbl\cf1\f51\fs20\qc Jurisdiction of Incorporation)\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc (Commission File Number)\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc (IRS Employer\par\pard\plain\intbl\cf1\f51\fs20\qc Identification No.)\cell{ {\trowd\cellx3456\cellx3672\cellx7128\cellx7343\cellx10800\trrh495\row}}}\pard\plain\fi594\cf1\f51\fs20\ql \~ \par\pard\plain {\trowd\clbrdrb\brdrs\brdrcf1\cellx10800\trrh495 \pard\plain\intbl\cf1\f51\fs20\qc 6800 Broken Sound Parkway NW, Third Floor\par\pard\plain\intbl\cf1\f51\fs20\qc Boca Raton, FL 33487\cell{ {\trowd\clbrdrb\brdrs\brdrcf1\cellx10800\trrh495\row}}} {\trowd\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\qc (Address of Principal Executive Office) (Zip Code)\cell{ {\trowd\cellx10800\trrh248\row}}}\pard\plain\fi594\cf1\f51\fs20\qc \~\par\pard\plain\cf1\f51\fs20\qc Registrant's telephone number, including area code: (561) 961-1900\par\pard\plain\fi594\cf1\f51\fs20\qc \~\par\pard\plain\cf1\f51\fs20\qj Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the\plain\cf1\f51\fs20\qj registrant under any of the following provisions (\plain\cf1\f51\fs20\i\qj see\plain\sa308\cf1\f51\fs20\qj General Instruction A.2 below):\par\pard\plain\cf1\f51\fs20\qj \u9744?\~\~Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\par\pard\plain\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\qj \u9744?\~\~Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\par\pard\plain\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\qj \u9744?\~\~Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\par\pard\plain\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\qj \u9744?\~\~Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\par\pard\plain\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\qj Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of\plain\cf1\f51\fs20\qj 1933 (\u167? 230-405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u167?240.12b-2 of this chapter).\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Emerging growth company \u9744?\par\pard\plain\cf1\f51\fs20\qr \~\par\pard\plain\cf1\f51\fs20\ql If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for\plain\cf1\f51\fs20\ql complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.\plain\cf1\f51\fs20\ql \u9744?\par\pard\plain\cf1\f51\fs20\ql \~ \par\pard\plain {\trowd\cellx3564\cellx7235\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{ {\trowd\cellx3564\cellx7235\cellx10800\trrh248\row}}} \page \par\pard\plain {\trowd\clvertalc\cellx10800\trrh248 \pard\plain\intbl\brdrb\brdrs\cf1\f51\fs20\qc \~\cell{ {\trowd\clvertalc\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart part_1_2_1}{\*\bkmkend part_1_2_1}{\*\bkmkstart item_1_41_1}{\*\bkmkend item_1_41_1} \par\pard\plain {\trowd\cellx1706\cellx10800\trrh495 \pard\plain\intbl\cf1\f51\fs20\b\ql Item 5.02.\cell\pard\plain\intbl\cf1\f51\fs20\b\qj Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;\plain\intbl\cf1\f51\fs20\b\qj Compensatory Arrangements of Certain Officers.\cell{ {\trowd\cellx1706\cellx10800\trrh495\row}}}\pard\plain\fi594\cf1\f51\fs20\qj On March 27, 2018, the Board of Directors (the \u8220?\plain\cf1\f51\fs20\ul\qj Board\plain\cf1\f51\fs20\qj \u8221?) of TherapeuticsMD, Inc., a Nevada corporation\plain\cf1\f51\fs20\qj (the \u8220?\plain\cf1\f51\fs20\ul\qj Company\plain\sa286\cf1\f51\fs20\qj \u8221?), appointed Ms. Jane F. Barlow, M.D., M.B.A, M.P.H. to serve as a director of the Company.\par\pard\plain\fi594\cf1\f51\fs20\qj The Board has determined that Dr. Barlow is independent under the rules of the NASDAQ Global Select Market.\par\pard\plain\fi594\cf1\f51\fs20\qj \~\par\pard\plain\fi594\cf1\f51\fs20\qj As director of the Company, Dr. Barlow will receive compensation in the same manner as the Company\u8217?s other\plain\sa286\cf1\f51\fs20\qj non-employee directors.\~\~\par\pard\plain\sa286\fi594\cf1\f51\fs20\qj Dr. Barlow has not been appointed to any committees of the Board at this time.\par\pard\plain\fi594\cf1\f51\fs20\qj There are no arrangements or understandings between Dr. Barlow and any other person pursuant to which Dr. Barlow was\plain\cf1\f51\fs20\qj appointed as a director of the Company. Other than as described in this Current Report on Form 8-K, since the beginning of the\plain\cf1\f51\fs20\qj Company\u8217?s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or\plain\cf1\f51\fs20\qj series of similar transactions, in which Dr. Barlow was or is to be a participant and in which any related person had a direct or\plain\sa286\cf1\f51\fs20\qj indirect material interest in which the amount involved exceeds or exceeded $120,000. \par\pard\plain {\trowd\cellx1706\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\b\ql Item 7.01.\cell\pard\plain\intbl\cf1\f51\fs20\b\qj Regulation FD Disclosure.\cell{ {\trowd\cellx1706\cellx10800\trrh248\row}}}\pard\plain\fi594\cf1\f51\fs20\qj On April 2, 2018, the Company issued a press release announcing the appointment of Ms. Jane F. Barlow, M.D., M.B.A,\plain\cf1\f51\fs20\qj M.P.H. to the Board. A copy of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and is\plain\cf1\f51\fs20\qj incorporated herein by reference. The information furnished in Item 7.01 of this Current Report on Form 8-K shall not be\plain\cf1\f51\fs20\qj deemed to be \u8220?filed\u8221? for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise\plain\cf1\f51\fs20\qj subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the\plain\sa242\cf1\f51\fs20\qj Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.{\*\bkmkstart part_1_2_2}{\*\bkmkend part_1_2_2}{\*\bkmkstart item_1_47_1}{\*\bkmkend item_1_47_1} \par\pard\plain {\trowd\cellx1706\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\b\ql Item 9.01.\cell\pard\plain\intbl\cf1\f51\fs20\b\ql Financial Statements and Exhibits.\cell{ {\trowd\cellx1706\cellx10800\trrh248\row}}}\pard\plain\li594\ri594\sb594\fi594\cf1\f51\fs20\qj (d)\~\~\~\~\plain\li594\ri594\sa594\cf1\f51\fs20\i\qj Exhibits.\par\pard\plain\cf1\f51\fs20\ql \~\~\par\pard\plain\cf1\f51\fs20\qc Exhibit Index\par\pard\plain\cf1\f51\fs20\ql \~ \par\pard\plain {\trowd\cellx1706\cellx1846\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ul\ql Exhibit Number\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ul\ql Description\cell{ {\trowd\cellx1706\cellx1846\cellx10800\trrh248\row}}} {\trowd\cellx1706\cellx1846\cellx10800\trrh371 \pard\plain\intbl\sb110\cf1\f51\fs20\ql 99.1\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\sb110\ul{\field{\*\fldinst HYPERLINK \\l "doc_1_2" }{\*\fldrslt\cf3\f51\fs20\ql Press release dated April 2, 2018.}}\cell{ {\trowd\cellx1706\cellx1846\cellx10800\trrh371\row}}}\pard\plain\cf1\f51\fs20\b\qc \~ \par\pard\plain {\trowd\cellx3564\cellx7235\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{ {\trowd\cellx3564\cellx7235\cellx10800\trrh248\row}}} \page \par\pard\plain {\trowd\clvertalc\cellx10800\trrh248 \pard\plain\intbl\brdrb\brdrs\cf1\f51\fs20\qc \~\cell{ {\trowd\clvertalc\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart part_1_2_3}{\*\bkmkend part_1_2_3}\par\pard\plain\sa264\cf1\f51\fs20\b\qc SIGNATURES\par\pard\plain\fi638\cf1\f51\fs20\qj Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be\plain\cf1\f51\fs20\qj signed on its behalf by the undersigned hereunto duly authorized.\par\pard\plain\fi638\cf1\f51\fs20\qj \~ \par\pard\plain {\trowd\cellx5341\cellx10799\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql Date:\~\~April 2, 2018\cell\pard\plain\intbl\cf1\f51\fs20\ql THERAPEUTICSMD, INC.\cell{ {\trowd\cellx5341\cellx10799\trrh248\row}}} {\trowd\cellx5341\cellx10799\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{ {\trowd\cellx5341\cellx10799\trrh248\row}}} {\trowd\cellx5341\cellx6311\clbrdrb\brdrs\brdrcf1\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql By:\cell\pard\plain\intbl\cf1\f51\fs20\ql /s/\plain\intbl\cf1\f51\fs20\i\ql Daniel A. Cartwright\cell{ {\trowd\cellx5341\cellx6311\clbrdrb\brdrs\brdrcf1\cellx10800\trrh248\row}}} {\trowd\cellx5341\cellx6311\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Name:\cell\pard\plain\intbl\cf1\f51\fs20\ql Daniel A. Cartwright\cell{ {\trowd\cellx5341\cellx6311\cellx10800\trrh248\row}}} {\trowd\cellx5341\cellx6311\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Title:\cell\pard\plain\intbl\cf1\f51\fs20\ql Chief Financial Officer\cell{ {\trowd\cellx5341\cellx6311\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~ \par\pard\plain {\trowd\cellx3564\cellx7235\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{ {\trowd\cellx3564\cellx7235\cellx10800\trrh248\row}}} \page{\*\bkmkstart doc_1_2}{\*\bkmkend doc_1_2}\pard\plain\brdrb\brdrs\cf1\f51\fs2\ql \~\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "doc_1_1" }{\*\fldrslt\cf3\f51\fs20\ql TherapeuticsMD, Inc. 8-K}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qr Exhibit 99.1\par\pard\plain\cf1\f51\fs20\b\qr \~\par\qr\li6028\sb88{\*\shppict{\pict\pngblip\picw581\pich67\picscalex34\picscaley34\bliptag-7471108711 {\*\blipuid bef9f207deaeebe6c3ae4089a8852a6d}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}} \par\pard\plain\li6908\sb88\cf1\f51\fs20\qr \~\par\pard\plain\li110\ri1936\sb44\cf1\f51\fs20\ql FOR IMMEDIATE RELEASE\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li88\ri88\cf1\f51\fs20\b\qc TherapeuticsMD Announces Expansion of Board of Directors\par\pard\plain\li88\ri88\cf1\f51\fs20\b\qc \~\par\pard\plain\cf1\f51\fs20\i\qc - Dr. Jane F. Barlow Appointed as Independent Director -\par\pard\plain\ri110\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\b\qj BOCA RATON, Florida, April 2, 2018\plain\cf1\f51\fs20\qj \u8211? TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women\u8217?s\plain\cf1\f51\fs20\qj healthcare company, today announced the appointment of Jane F. Barlow, M.D., M.B.A., M.P.H. as an independent director to\plain\cf1\f51\fs20\qj the Board of Directors.\par\pard\plain\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\qj Dr. Barlow previously served as Associate Chief Medical Officer for CVS Health and Chief Medical Officer of CVS\plain\cf1\f51\fs20\qj Health\u8217?s Medicare and Government Services business segment, where she drove clinical strategies supporting drug\plain\cf1\f51\fs20\qj purchasing, distribution, and utilization management for over five billion annual prescriptions. Prior to CVS Health, she served as\plain\cf1\f51\fs20\qj Vice President of Clinical Innovation at MEDCO Health Solutions, focused on clinical innovations into all aspects of pharmacy\plain\cf1\f51\fs20\qj and pharmacy benefits management for over 60 million members. Dr. Barlow is currently the Chief Executive Officer of Jane\plain\cf1\f51\fs20\qj Barlow & Associates, LLC.\par\pard\plain\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\qj Dr. Barlow is a clinical and strategic executive with over 25 years of leadership experience in driving cost-effective medical,\plain\cf1\f51\fs20\qj diagnostic, and pharmaceutical strategies, directing corporate health benefits, delivering patient care, and supporting health\plain\cf1\f51\fs20\qj systems. She is a recognized leader in payer reimbursement, health policy, technology, quality and compliance, benefits design,\plain\cf1\f51\fs20\qj and population health management. Dr. Barlow is active in evaluating the economic impact and value of pharmaceuticals and\plain\cf1\f51\fs20\qj diagnostics to aid payers and manufacturers in defining access and coverage strategies.\par\pard\plain\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\qj \u8220?We are very pleased to add Dr. Barlow as the newest independent director to our Board. She has a wealth of experience\plain\cf1\f51\fs20\qj as both a director and a member of senior management at successful healthcare organizations,\u8221? said TherapeuticsMD CEO\plain\cf1\f51\fs20\qj Robert G. Finizio. \u8220?This is an exciting time in our company\u8217?s growth and development, and Dr. Barlow\u8217?s\plain\cf1\f51\fs20\qj skill set complements our transformation to a commercial organization in the years ahead.\u8221?\par\pard\plain\ri110\cf1\f51\fs20\qj \~\par\pard\plain\cf1\f51\fs20\b\qj About TherapeuticsMD, Inc.\par\pard\plain\cf1\f51\fs20\b\qj \~\par\pard\plain\cf1\f51\fs20\qj TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for\plain\cf1\f51\fs20\qj women. With its SYMBODA\u8482? technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical\plain\cf1\f51\fs20\qj products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The\plain\cf1\f51\fs20\qj Company\u8217?s late stage clinical pipeline includes two product candidates that have completed phase 3 trials and are awaiting\plain\cf1\f51\fs20\qj approval by the FDA: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and\plain\cf1\f51\fs20\qj TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and\plain\cf1\f51\fs20\qj vaginal atrophy (VVA) due to menopause. The Company also manufactures and distributes branded and generic prescription\plain\cf1\f51\fs20\qj prenatal vitamins under the vitaMedMD\u174? and BocaGreenMD\u174? brands.\par\pard\plain\cf1\f51\fs20\qj \~ \par\pard\plain {\trowd\clvertalc\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\qc \~\cell{ {\trowd\clvertalc\cellx10800\trrh248\row}}} \page \par\pard\plain {\trowd\clvertalc\cellx10800\trrh248 \pard\plain\intbl\brdrb\brdrs\cf1\f51\fs20\qc \~\cell{ {\trowd\clvertalc\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\i\qj \~\par\pard\plain\cf1\f51\fs20\b\qj Forward-Looking Statements\par\pard\plain\cf1\f51\fs20\b\qj \~\par\pard\plain\cf1\f51\fs20\i\qj This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include,\plain\cf1\f51\fs20\i\qj but are not limited to, statements relating to TherapeuticsMD\u8217?s objectives, plans and strategies as well as statements,\plain\cf1\f51\fs20\i\qj other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or\plain\cf1\f51\fs20\i\qj anticipates will or may occur in the future. These statements are often characterized by terminology such as\plain\cf1\f51\fs20\i\qj \u8220?believes,\u8221? \u8220?hopes,\u8221? \u8220?may,\u8221? \u8220?anticipates,\u8221? \u8220?should,\u8221?\plain\cf1\f51\fs20\i\qj \u8220?intends,\u8221? \u8220?plans,\u8221? \u8220?will,\u8221? \u8220?expects,\u8221? \u8220?estimates,\u8221?\plain\cf1\f51\fs20\i\qj \u8220?projects,\u8221? \u8220?positioned,\u8221? \u8220?strategy\u8221? and similar expressions and are based on\plain\cf1\f51\fs20\i\qj assumptions and assessments made in light of management\u8217?s experience and perception of historical trends, current\plain\cf1\f51\fs20\i\qj conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press\plain\cf1\f51\fs20\i\qj release are made as of the date of this press release, and the company undertakes no duty to update or revise any such\plain\cf1\f51\fs20\i\qj statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of\plain\cf1\f51\fs20\i\qj future performance and are subject to risks and uncertainties, many of which are outside of the company\u8217?s control.\plain\cf1\f51\fs20\i\qj Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking\plain\cf1\f51\fs20\i\qj statements are described in the sections titled \u8220?Risk Factors\u8221? in the company\u8217?s filings with the Securities and\plain\cf1\f51\fs20\i\qj Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well\plain\cf1\f51\fs20\i\qj as reports on Form 8-K, and include the following: the company\u8217?s ability to resolve the deficiencies identified by the\plain\cf1\f51\fs20\i\qj FDA in the company\u8217?s new drug application for its TX-004HR product candidate and the time frame associated with\plain\cf1\f51\fs20\i\qj such resolution; whether the FDA will approve the amended NDA for the company\u8217?s TX-004HR product candidate and\plain\cf1\f51\fs20\i\qj whether such approval will occur by the PDUFA target action date; whether the FDA will approve the NDA for the\plain\cf1\f51\fs20\i\qj company\u8217?s TX-001HR product candidate and whether such approval will occur by the PDUFA target action date; the\plain\cf1\f51\fs20\i\qj company\u8217?s ability to maintain or increase sales of its products; the company\u8217?s ability to develop and commercialize\plain\cf1\f51\fs20\i\qj its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of\plain\cf1\f51\fs20\i\qj the company\u8217?s clinical trials, including any additional clinical trials that the FDA may require in connection with\plain\cf1\f51\fs20\i\qj TX-004HR; the potential of adverse side effects or other safety risks that could preclude the approval of the company\u8217?s\plain\cf1\f51\fs20\i\qj hormone therapy drug candidates; the company\u8217?s reliance on third parties to conduct its clinical trials, research and\plain\cf1\f51\fs20\i\qj development and manufacturing; the availability of reimbursement from government authorities and health insurance companies\plain\cf1\f51\fs20\i\qj for the company\u8217?s products; the impact of product liability lawsuits; the influence of extensive and costly government\plain\cf1\f51\fs20\i\qj regulation; the volatility of the trading price of the company\u8217?s common stock and the concentration of power in its stock\plain\cf1\f51\fs20\i\qj ownership. PDF copies of the company\u8217?s historical press releases and financial tables can be viewed and downloaded at\plain\cf1\f51\fs20\i\qj its website: www.therapeuticsmd.com/pressreleases.aspx.\par\pard\plain\cf1\f51\fs20\qc \~\par\pard\plain\cf1\f51\fs20\qc # # #\par\pard\plain\li110\fi-110\cf1\f51\fs20\b\ql \~\par\pard\plain\li110\fi-110\cf1\f51\fs20\b\ul\ql Investor Contact\par\pard\plain\ri6424\cf1\f51\fs20\ql \~\par\pard\plain\ri6424\cf1\f51\fs20\ql David DeLucia\par\pard\plain\ri6424\cf1\f51\fs20\ql Director, Investor Relations\par\pard\plain\cf1\f51\fs20\qj 561-961-1900 \par\pard\plain\fs16\pard\plain\cf1\f51\fs20\qj David.DeLucia@TherapeuticsMD.com\~\par\pard\plain\ri6028\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qj \~ \par\pard\plain {\trowd\clvertalc\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\qc \~\cell{ {\trowd\clvertalc\cellx10800\trrh248\row}}}\pard\plain\brdrb\brdrs\cf1\f51\fs20\b\ql \~}